

FORM PTO-1449  
MODIFIEDU.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY/DOCKET NO.  
207596APPLICATION NO.  
09/720,276INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Erickson et al.

MAR 26 2001

(Use several sheets if necessary)

FILING DATE  
December 21, 2000GROUP  
Unassigned 1648

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		APPLICATION OR PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ele	AA	5,766,842	06/16/1998	Heefner et al.			
	AB	5,753,660	05/19/1998	Sikorski et al.			
	AC	5,728,718	03/17/1998	Randad et al.			
	AD	5,723,490	03/03/1998	Tung			
	AE	5,705,500	01/06/1998	Getman et al.			
	AF	5,703,076	12/30/1997	Talley et al.			
	AG	5,502,060	3/26/1996	Thompson			
	AH	5,475,027	12/12/1995	Talley et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO*+
ele	AI	WO 99/67417	12/29/1999	WIPO				
	AJ	WO 99/67254	12/29/1999	WIPO				
	AK	WO 99/65870	12/23/1999	WIPO				
ele	AL	WO 97/19055	05/29/1997	WIPO				
	AM	WO 96/28463	09/16/1996	WIPO				
	AN	WO 95/06030	03/02/1995	WIPO				
	AO	2,276,621	10/05/1994	UK				
	AP	WO 94/14793	07/07/1994	WIPO				
	AQ	WO 94/05639	03/17/1994	WIPO				
	AR	WO 94/04492	03/03/1994	WIPO				
	AS	WO 90/09191	08/23/1990	WIPO	~+			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT	Bone et al., <i>J Am Chem Soc</i> , 113, 9382 (1991)
ele AU	Borman et al., <i>J. Gen. Virology</i> , 77(3), 419-426 (March 1996)
AV	Erickson et al., <i>Science</i> , 249, 527-533 (1990)
AW	Ghosh et al., <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 8, 687-690 (March 1998)
AX	Ghosh et al., <i>J. Medicinal Chemistry</i> , 36(16), 2300-2310 (August 1993)
AY	Ghosh et al., <i>J. Medicinal Chemistry</i> , 36(2), 292-294 (January 1993)
AZ	Ghosh et al., <i>J. Medicinal Chemistry</i> , 37(16), 2506-2508 (August 1994)
BA	Ghosh et al., <i>J. Medicinal Chemistry</i> , 37, 1177-1188 (April 1994)
BB	Gulnik et al., <i>Biochemistry</i> , 34(29), 9282-9287 (July 1995)
BC	Ho et al., <i>J. Virology</i> , 68(3), 2016-2020 (March 1994)
BD	Huff, <i>J. Med. Chem.</i> , 34(8), 2305-2314 (August 1991)
BE	Kageyama et al., <i>Antimicrob Agents Chemother</i> , 36, 926-933 (May 1992)
BF	Kaplan et al., <i>PNAS USA</i> , 91, 5397-5401 (1994)

FORM PTO-1449

MODIFIED

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY/DOCKET NO.  
207596APPLICATION NO.  
09/720,276INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
Erickson et al.FILING DATE  
December 21, 2000GROUP  
Unassigned 1648

	BG	Kim et al., <i>J. Medicinal Chemistry</i> , 38(17), 1181-1182 (1995) →
ele	BH	Klabe et al., <i>Biochemistry</i> , 37(24), 8735-8742 (May 1998)
✓	BI	Kramer et al., <i>Science</i> , 231, 1580-1584 (1996) →
✓	BJ	Lyle et al., <i>J. Med. Chem.</i> , 34(3), 1228-1230 (March 1991)
✓	BK	Majer et al., <i>73rd American Peptide Symposium</i> , Edmonton, Canada (1993)
ele	BL	Martinez-Picado et al. <i>J. Virology</i> , 73(5), 3744-3752 (May 1999)
✓	BM	McQuade et al., <i>Science</i> , 247, 454-456 (1990) →
✓	BN	Meek et al., <i>Nature</i> , 343(6253), 90-92 (January 1990) →
✓	BO	Meek, <i>J. Enzyme Inhibition</i> , 6(1), 65-98 (January 1992) →
✓	BP	Moore et al., <i>Perspect. Drug Dis. Design</i> , 1, 85-108 (1993) →
✓	BQ	Norbeck et al., <i>Ann. Reports Med. Chem.</i> , 26, 141-150 (1991) →
✓	BR	Otto et al., <i>PNAS USA</i> , 90, 7543-7547 (1993) →
✓	BS	Plattner et al., <i>Drug Discovery Technologies</i> , Clark et al., eds., Ellis Horwood, Chichester, England, 92-126 (1990)
✓	BT	Rich et al., <i>J. Med. Chem.</i> , 33(5), 1285-1288 (May 1990) →
✓	BU	Roberts et al., <i>Science</i> , 248, 358-361 (1990) →
✓	BV	Tomasselli et al., <i>Int. J. Chem. Biotechnology</i> , 6, 6-27 (1991) →
✓	BW	Vacca et al., <i>J. Med. Chem.</i> , 34(3), 1225-1228 (March 1991) →
✓	BX	Vazquez et al., <i>J. Medicinal Chemistry</i> , 38(4), 581-584 (February 1995) →

EXAMINER

*Erin M. De*

DATE CONSIDERED

*10/07/03*

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(b).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(b).